New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 15, 2012
08:57 EDTARQL, TRGTTargacept names Stephen A. Hill, M.D., president and CEO
Dr. Hill is expected to start with Targacept (TRGT) on December 1 and will also join Targaceptís Board of Directors. Dr. Hill brings over 20 years of industry experience to the role, having served previously as President and Chief Executive Officer of Solvay Pharmaceuticals, Inc. and ArQule (ARQL). Upon Dr. Hill joining Targacept, the previously formed Office of the Chairman will be dissolved.
News For TRGT;ARQL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2015
07:35 EDTARQLArQule reports enrollment of first patient in Phase 1 Proteus syndrome trial
ArQule and the National Human Genome Research Institute, or NHGRI, of the National Institutes of Health, or NIH, announced enrollment of the first patient in the phase 1 clinical trial for Proteus syndrome. This trial, with ARQ 092, an orally available, selective pan-AKT inhibitor, marks the first clinical trial in this rare disease. Proteus syndrome is characterized by overgrowth of the skeleton, skin, adipose tissue and central nervous system. Additionally, ArQule received orphan drug designation from the FDA for ARQ 092 in Proteus syndrome. This marks an important regulatory milestone and the first orphan drug designation for this population. Proteus syndrome impacts fewer than one in a million people worldwide.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use